<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02151942</url>
  </required_header>
  <id_info>
    <org_study_id>PRS-001</org_study_id>
    <nct_id>NCT02151942</nct_id>
  </id_info>
  <brief_title>Patient-Specific Simulation Used for EVAR Procedure Rehearsal - Evaluation of Clinical Performance With and Without Prior Rehearsal</brief_title>
  <acronym>PRS</acronym>
  <official_title>Patient-Specific Simulation Used for Case Rehearsal Prior to EVAR Procedure - Evaluation of Clinical Performance With and Without Prior Rehearsal Using the Procedure Rehearsal Studio. Multi-center Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simbionix US Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Simbionix US Corporation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the procedural and clinical benefits of patient
      specific pre-procedure rehearsal for operators with various experience levels as a tool for
      optimizing Endovascular Aneurysm Repair (EVAR) procedures.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Overall Fluoro time</measure>
    <time_frame>Within 4 hr. after EVAR procedure starts</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective operator perceived effectiveness of prior procedure rehearsal</measure>
    <time_frame>Within 4 hr. after EVAR procedure starts</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraprocedural safety measurements</measure>
    <time_frame>Within 4 hr. after EVAR procedure starts</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall contrast use (volume)
Skin entry radiation dose
Overall procedure time (from gaining bilateral access until the satisfactory completion of endograft deployment, excluding all adjunctive procedures such as hypogastric embolization, Iliac Percutaneous Transluminal Angioplasty (PTA)/Stenting, sheath removal and hemostasis time)
Procedural blood loss - number of transfused units
Arterial injury (dissection, perforation, rupture, surgical conversion, embolization, none)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in procedure plan</measure>
    <time_frame>Within 4 hr. after EVAR procedure rehearsal starts</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of treatment plans based on Customary (normal institutional) technique, following 3D reconstruction, and after simulation procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjunctive device utilization</measure>
    <time_frame>Within 4 hr. after EVAR procedure ends</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and type of used wires, catheters, stent grafts, additional stent graft components and balloons</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gate cannulation time</measure>
    <time_frame>Within 3 hr. after EVAR procedure starts</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time to cannulate the contralateral gate with a wire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Similarity of simulation to actual case</measure>
    <time_frame>Within 3 hr. after EVAR procedure ends</time_frame>
    <safety_issue>No</safety_issue>
    <description>Anatomy
Anticipated devices (sizing, tools)
Fluoroscopic Angulations
Case complexity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General satisfaction- Subjective experience of simulation experience</measure>
    <time_frame>Within 4 hr. after EVAR procedure ends</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall ease of use
Controls
Imaging
Device exchanges
Device performance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>Within the first 30 days after the EVAR procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical/Clinical success rate</measure>
    <time_frame>Within the first 30 days after the EVAR procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Successful endograft deployment and absence of type 1 or 3 endoleak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of simulator rehearsal</measure>
    <time_frame>Within 3 hr. after EVAR procedure rehearsal ends</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in ICU</measure>
    <time_frame>within 30 days after the EVAR procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Length of Stay</measure>
    <time_frame>Within 30 days after the EVAR procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infra Renal Aortic Aneurysm</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rehearsal group</arm_group_label>
    <description>Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects admitted for elective endovascular AAA repair will be randomized
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years old

          2. Elective patients planned to undergo EVAR procedures with an endograft compatible
             with the Simbionix PRS.

          3. Computed Tomography Angiography (CTA) scan of the abdominal aorta performed as
             standard of care.  Sufficient quality/defined protocol.

        Exclusion Criteria:

          1. Subject is below 18 years old

          2. Operator cannot complete the indicated rehearsal and practice.

          3. Patients requiring emergent aneurysm treatment, e.g. trauma or rupture.

          4. Arterial dissection.

          5. Patients with Stage 4 of chronic kidney disease (GFR&lt;30 ml/min/m2).

          6. Patient is indicated for use of snorkels, chimneys, fenestrated or branched graft
             devices

          7. Pregnant or lactating women.

          8. Off label stent graft use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John H. Rundback, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holy Name Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erez Ben Zvi</last_name>
    <phone>+972 54 669 0924</phone>
    <email>erez@simbionix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John H. Rundback, MD</last_name>
      <phone>201-833-7268</phone>
      <email>jrundback@airsllp.com</email>
    </contact>
    <contact_backup>
      <last_name>Ravit Barkama, MD</last_name>
      <phone>201-541-6312</phone>
      <email>barkama@mail.holyname.org</email>
    </contact_backup>
    <investigator>
      <last_name>John H. Rundback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elective endovascular AAA repair</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
